Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
How are you integrating Prostox into your practice for prostate patients deciding between SBRT and hypofractionation?
Related Questions
For patients undergoing bladder preservation therapy with TMT, how do you manage the urinary urgency and frequency during and after treatment?
What radiation treatments would you offer an older man with unfavorable intermediate-risk prostate cancer, with comorbid conditions, if you don't feel he is a good candidate for full-course radiation therapy with ADT?
Which genomic test do you choose for a patient with favorable intermediate prostate cancer trying to decide between active surveillance and treatment?
Would you offer focal prostate boost per FLAME protocol for GTV defined by PET alone without MRI?
Is it appropriate to offer definitive trimodality therapy, as an equivalent option to neoadjuvant chemotherapy followed by radical cystectomy, in patients with muscle-invasive bladder cancer regardless of fitness or platinum eligibility?
Do you include the prostate when treating bladder cancer?
How do you reconcile discrepancies in clinical prostate cancer staging with AJCC and NCCN?
How do you counsel NCCN low and very low risk prostate cancer patients who receive a high risk DECIPHER score?
I am curious why the most recent NCCN guidelines (Version 4.2024, 05/17/24) omit the duration of ADT for high-risk prostate cancer patients.
How do you sequence Ra-223 and Lu-177 in patients with mCRPC with predominantly bony disease?
